Molecular Cancer

Article	Citations
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	1317
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	811
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	759
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	734
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors	557
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	509
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	504
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	480
TGF-β signaling promotes cervical cancer metastasis via CDR1as	462
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	449
Immunotherapies in rare cancers	447
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	435
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	381
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	365
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	334
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6	292
CRISPR based therapeutics: a new paradigm in cancer precision medicine	259
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	256
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	253
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	250
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	247
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	241
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	241
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	232
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	231

The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	211
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	205
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	194
ERK mediates interferon gamma-induced melanoma cell death	193
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	186
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	175
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	173
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	171
Effects of RNA methylation on Tumor angiogenesis and cancer progression	169
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	168
Correction to: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs	162
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	160
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	153
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	153
Bidirectional role of neutrophils in tumor development	151
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	149
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	146
NK cells are never alone: crosstalk and communication in tumour microenvironments	146
Insights into N6-methyladenosine and programmed cell death in cancer	144
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	138
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	136
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	135
Emerging roles of tRNA-derived fragments in cancer	135
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis	132
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	130
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	130
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	128
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks	127
GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma	127
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer	126
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	123
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	123
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	123
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	120
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	119
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	116
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	115
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	114
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	114
Crosstalk between autophagy and microbiota in cancer progression	114
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma	112
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	111
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	111
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	109
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	108
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	108
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	106
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	105
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	104
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	103

Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	103
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	100
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	99
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	98
Molecular mechanisms of tumor resistance to radiotherapy	98
Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin	98
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	96
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	95
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	95
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	95
Correction to: Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma	92
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors	92
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	92
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	91
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	90
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	90
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	89
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	89
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions	88
Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape	88
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy	87
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response	87
Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases	87
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	87
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	87
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer	86
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives	85
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	84
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway	84
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges	83
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer	83
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	83
CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma	82
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma	81
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	81
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis	81
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond	81
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma	80
PRMT7: a survive-or-die switch in cancer stem cells	80
Retraction Note: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer	80
A high proportion of germline variants in pediatric chronic myeloid leukemia	80
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer	79
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway	78
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation	77
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better	77
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective	77
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy	76
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma	76
Exosomal miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2	75
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination	74
CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals	74
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells	74
Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4–HDAC4–RUNX2–GAMT-mediated apoptosis	73
DNA methylation-associated dysregulation of transfer RNA expression in human cancer	72
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	72
Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	71
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling	71
Biological and pharmacological roles of m6A modifications in cancer drug resistance	70
EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling	70
Inflammation in cancer: therapeutic opportunities from new insights	70
Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine	70
Glioma targeted therapy: insight into future of molecular approaches	70
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development	69
CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis	69
Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma	69
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis	69
Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target	69
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy	68
Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance	68
Correction: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression	67
Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis	66
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer	66
Shifting landscapes of gender equity in oncology journals: a decade of authorship trends	66
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research	66
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy	65
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer	65
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors	65
Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network	65
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment	65
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma	64

Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway	63
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	62
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies	62
Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency	62
CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis	61
Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway	61
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis	61
AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway	60
Proteomics technologies for cancer liquid biopsies	60
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells	60
The role of m6A RNA methylation in cancer metabolism	59
Exploiting innate immunity for cancer immunotherapy	59
Targeting TGF-β signal transduction for fibrosis and cancer therapy	59
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	58
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	58
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	58
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer	57
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	57
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	57
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	57
Extracellular vesicles in tumor immunity: mechanisms and novel insights	56
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation	56
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	56
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	56
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	56
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	56
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates	55
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	55
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	55
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	55
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	54
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	54
Expression of mTOR in normal and pathological conditions	54
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	53
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	52
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	51
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	51
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	51
Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer	50
Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells	50
circRNAs shed light on cancer diagnosis and treatment	50
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	50
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	50
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine	50
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	49
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations	49
Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion	49
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	48
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer	47
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications	47
Transfer RNA-derived small RNAs in tumor microenvironment	47
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	47
The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy	47
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy	46
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	46
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	46
The intersection of COVID-19 and cancer: signaling pathways and treatment implications	46
Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop	46
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy	46
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring	45
CAR T cells: engineered immune cells to treat brain cancers and beyond	45
Writers, readers, and erasers RNA modifications and drug resistance in cancer	45
Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop	44
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy	44
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	43
Advances in immunotherapy for triple-negative breast cancer	43
The epigenetic hallmarks of immune cells in cancer	43
BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion	43
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2	43
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study	42
The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance	42
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	42
Retraction Note: N6-methyladenosine induced mir-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1	42
The journey of CAR-T therapy in hematological malignancies	42
Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection	41
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer	41
Correction: CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug	41
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer	41
Spatial transcriptomic analysis of tumor microenvironment in esophageal squamous cell carcinoma with HIV infection	41
Commentary on “Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth”	41
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer	40
R-loops’ m6A modification and its roles in cancers	40
Pan-cancer drivers of metastasis	40
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia	40
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer	40
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy	40
ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer	40
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC	40
Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma	40
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer	40
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study	40